NTT-DOCOMO
16.1.2024 10:11:27 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2024, the world's largest mobile exhibition, in Barcelona, Spain from February 26 to 29. DOCOMO's booth will showcase exhibits of its technological advancement since last year and presentations focused on the core themes of 6G, open radio access networks (Open RAN) and extended reality (XR), aiming to advance international standardization and foster global business opportunities with the implementation of next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116090399/en/
NTT DOCOMO Booth at MWC Barcelona 2024 (Graphic: Business Wire)
For 6G, there will be interactive demonstrations of FEEL TECH,® an innovative technology that revolutionizes the sharing of sensory information between people DOCOMO's Human Augmentation Platform connected to a 6G network. This pioneering technology aims to facilitate clear transmission of sensory information that is often difficult to communicate verbally, paving the way for a new communication culture and providing added value for an enhanced quality of life.
The booth will also provide a glimpse of the coming world of 6G and advanced wireless technologies that DOCOMO is now developing, such as a non-terrestrial network (NTN) incorporating high-altitude platform stations (HAPS),1 which are expected to facilitate the broad extension of communication services beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
For Open RAN, in addition to presenting the OREX®2-branded services (OREX Packages), DOCOMO will introduce the latest initiatives with diverse global vendors and operators since the launch of the OREX to make Open RAN a reality.
For XR, DOCOMO will showcase the first concept model3 of XR glasses from NTT QONOQ Devices, INC.,4 which is scheduled for release around mid-2024, along with images of utilization.
At MWC Barcelona 2024, DOCOMO looks forward to showcasing its cutting-edge technologies and businesses the company is developing under the brand slogan "changing worlds with you."
For more about DOCOMO's exhibits and the overall exhibition, please refer to the appendix.
1 Unmanned vehicles flying in the stratosphere for days or months at a time, using relays to provide mobile connectivity (ranging up to 200 kilometers) in mountainous and remote areas, including at sea and in the air, on a highly cost-efficient basis.
2 OREX Announces OREX® Open RAN Service Lineup https://www.docomo.ne.jp/english/info/media_center/pr/2023/0927_00.html
3 Specifications of final commercial products may differ from the reference exhibits.
4 NTT QONOQ, INC. and SHARP CORPORATION form a joint venture company, NTT QONOQ Devices, INC.
https://www.devices.nttqonoq.com/pdf/20230327.pdf
Human Augmentation Platform, FEEL TECH and OREX are registered trademarks of NTT DOCOMO, INC. in Japan.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2024
1. Exhibitions |
||
Theme |
Exhibit & Demo |
Details |
6G |
Wireless technologies and NTN |
Non-terrestrial network initiatives for 6G and extended coverage, including technical explanations, dioramas and simulators. |
Human Augmentation Platform |
Platform and FEEL TECH technology for sharing sensory information between people. |
|
Open RAN |
Virtual tour of Shared Open Lab |
360-degree, 3D virtual tour of the OREX verification environment. |
Automated network design and maintenance |
Demonstrations of actual systems for automated network design and maintenance. |
|
XR |
Conceptual model of XR glasses |
Mock-up model and video illustrating how these proposed glasses will be used. |
2. NTT DOCOMO Booth Location
Hall 4 Stand 4E50
3. Presentation
Tentative title: Open RAN: Toward Commercialization and Operations
When: Monday, February 26 from 13:15 to 13:45 (local time)
Where: Broadcast Stage, Hall 4
Speaker: Mr. Sadayuki Abeta, OREX evangelist, NTT DOCOMO
Note: Content and schedule are subject to change. Please see MWC Barcelona 2024 for the latest information.
Reference
MWC Barcelona 2024
https://www.mwcbarcelona.com/
1. Dates & Times
February 26 to 29
08:30 to 19:00, but 08:30 to 16:00 on last day (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116090399/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom